Use of weekly, low dose, high frequency ultrasound for hard to heal venous leg ulcers: the VenUS III randomised controlled trial

2012 ◽  
Vol 2012 ◽  
pp. 109-111
Author(s):  
D.E. Feldman
BMJ ◽  
2011 ◽  
Vol 342 (mar08 2) ◽  
pp. d1092-d1092 ◽  
Author(s):  
J. M. Watson ◽  
A. R. Kang'ombe ◽  
M. O. Soares ◽  
L.-H. Chuang ◽  
G. Worthy ◽  
...  

2020 ◽  
Vol 17 (3) ◽  
pp. 742-752 ◽  
Author(s):  
Paul D. Hayes ◽  
Keith G. Harding ◽  
Susan M. Johnson ◽  
Charles McCollum ◽  
Luc Téot ◽  
...  

2009 ◽  
Vol 96 (S1) ◽  
pp. 15-15
Author(s):  
J. A. Michaels ◽  
B. King ◽  
J. B. MacIntyre ◽  
S. J. Palfreyman ◽  
P. M. Shackley ◽  
...  

BMJ Open ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. e043420
Author(s):  
Andrew Jull ◽  
Angela Wadham ◽  
Chris Bullen ◽  
Varsha Parag ◽  
John G M Parsons ◽  
...  

IntroductionCompression is the mainstay of treatment for venous leg ulcers (VLUs) and there are few effective adjuvant treatments. There is only observational evidence supporting the use of hypochlorous acid (HOCl) as a topical wound solution on VLU and some limited randomised evidence for the effect of a prescribed regimen of exercise.Methods and analysisThe Factorial4VLU trial is a pragmatic, blinded, factorial randomised controlled trial, with 380 participants receiving either a prescribed exercise regimen compared with usual care and either active HOCl wound solution or placebo wound solution at each dressing change for up to 24 weeks. All participants will receive compression therapy. The primary outcome is the proportion of participants with healed VLU at 12 weeks after randomisation as adjudicated by blinded review of ulcer photographs. Secondary outcomes are proportion healed at 24 weeks, time to healing, estimated change in ulcer area, change in 2-Minute Walk Test, change in health-related quality of life, incidence of infection and incidence of all-cause adverse events. If either of the interventions shows a statistically significant positive difference on healing outcomes, cost-effectiveness will be modelled using a health service perspective.Ethics and disseminationThe Factorial4VLU trial received ethical approval from the Northern B Health and Disability Ethics Committee. We plan to publish the results within 1 year of trial completion and will include the results on the trial registration page.Trial registration numbersAustralia and New Zealand Clinical Trials Register (http://www.anzctr.org.au) (ACTRN12620000116921); Universal Trial Number (WHO) (U1111-1236-2997).


Sign in / Sign up

Export Citation Format

Share Document